Zusammensetzungen und Verwendung eines Fibrinogenbindenden Motivs, das in Efb und Coa Vorhanden Ist, für Therapeutika und Impfstoffe gegen Staphylococcus Aureus

Details

Veröffentlichungs-Nr.

EP3922644

Aktenzeichen

EP21174829

Anmeldetag

19. Mai 2021

Veröffentlichung

13. April 2022

Rechtsraum

EP

IPC

C07K16/12A61P31/04

Abstract

The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.

Anmelder

Firmen

The Texas A&M University System
Universita' Degli Studi Di Pavia
Technische Universität Braunschweig
University Medical Center Utrecht, The Netherlands

Land

🇺🇸 USA

Fachgebiete